Details of the Drug

General Information of Drug (ID: DM0RKS4)

Drug Name
Bepridil
Synonyms
Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline
Indication
Disease Entry ICD 11 Status REF
Chronic/stable angina BA40.1 Approved [1], [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 366.5
Topological Polar Surface Area (xlogp) 5.3
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
61% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.7 mL/min/kg [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 24 - 50 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.19663 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.001% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 10.1 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 5 mg/mL [3]
Chemical Identifiers
Formula
C24H34N2O
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline
Canonical SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
InChIKey
UIEATEWHFDRYRU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2351
ChEBI ID
CHEBI:3061
CAS Number
64706-54-3
DrugBank ID
DB01244
TTD ID
D0Y4JJ
VARIDT ID
DR00709
INTEDE ID
DR0202

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bepridil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Bepridil and Ivabradine. Angina pectoris [BA40] [44]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Bepridil and Dronedarone. Angina pectoris [BA40] [45]
Coadministration of a Drug Treating the Disease Different from Bepridil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Bepridil and Ivosidenib. Acute myeloid leukaemia [2A60] [45]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Bepridil and Midostaurin. Acute myeloid leukaemia [2A60] [45]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Bepridil and Arn-509. Acute myeloid leukaemia [2A60] [45]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Bepridil and Gilteritinib. Acute myeloid leukaemia [2A60] [45]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Bepridil and Oliceridine. Acute pain [MG31] [45]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Bepridil and Posaconazole. Aspergillosis [1F20] [45]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Bepridil and Levalbuterol. Asthma [CA23] [46]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Bepridil and Pirbuterol. Asthma [CA23] [46]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Bepridil and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [45]
Dalfopristin DM4LTKV Major Decreased metabolism of Bepridil caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Bepridil and Retigabine. Behcet disease [4A62] [45]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Bepridil and Cariprazine. Bipolar disorder [6A60] [48]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Bepridil and Eribulin. Breast cancer [2C60-2C6Y] [45]
Talazoparib DM1KS78 Moderate Decreased clearance of Bepridil due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [45]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Bepridil and Lapatinib. Breast cancer [2C60-2C6Y] [45]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Bepridil and Bosutinib. Breast cancer [2C60-2C6Y] [45]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Bepridil and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [45]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Bepridil and Vilanterol. Chronic obstructive pulmonary disease [CA22] [46]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Bepridil and Indacaterol. Chronic obstructive pulmonary disease [CA22] [49]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Bepridil and Arformoterol. Chronic obstructive pulmonary disease [CA22] [49]
Fidaxomicin DMFP6MV Minor Decreased clearance of Bepridil due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [50]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Bepridil and Pasireotide. Cushing syndrome [5A70] [45]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Bepridil and Osilodrostat. Cushing syndrome [5A70] [45]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Bepridil caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [51]
MK-8228 DMOB58Q Moderate Decreased metabolism of Bepridil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [52]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Bepridil caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [53]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Bepridil and Isocarboxazid. Depression [6A70-6A7Z] [54]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Bepridil and OPC-34712. Depression [6A70-6A7Z] [48]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Bepridil and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [45]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Bepridil and Deutetrabenazine. Dystonic disorder [8A02] [45]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Bepridil and Ingrezza. Dystonic disorder [8A02] [45]
Cenobamate DMGOVHA Moderate Increased metabolism of Bepridil caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Fosphenytoin DMOX3LB Major Increased metabolism of Bepridil caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Bepridil and Solifenacin. Functional bladder disorder [GC50] [45]
Ripretinib DM958QB Moderate Decreased clearance of Bepridil due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [57]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Bepridil and Sunitinib. Gastrointestinal stromal tumour [2B5B] [45]
Simeprevir DMLUA9D Moderate Decreased metabolism of Bepridil caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [58]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Bepridil caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Bepridil and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [45]
Cobicistat DM6L4H2 Major Decreased metabolism of Bepridil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Etravirine DMGV8QU Moderate Increased metabolism of Bepridil caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Bepridil and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [45]
Darunavir DMN3GCH Moderate Decreased metabolism of Bepridil caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Aliskiren DM1BV7W Moderate Decreased clearance of Bepridil due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [45]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Bepridil and Nebivolol. Hypertension [BA00-BA04] [62]
Tolvaptan DMIWFRL Moderate Decreased clearance of Bepridil due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [63]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Bepridil and ITI-007. Insomnia [7A00-7A0Z] [48]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Bepridil and Polyethylene glycol. Irritable bowel syndrome [DD91] [64]
Naloxegol DML0B41 Minor Decreased clearance of Bepridil due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [65]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Bepridil and Crizotinib. Lung cancer [2C25] [45]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Bepridil and Osimertinib. Lung cancer [2C25] [45]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Bepridil and Selpercatinib. Lung cancer [2C25] [45]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Bepridil and Lumefantrine. Malaria [1F40-1F45] [57]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Bepridil and Hydroxychloroquine. Malaria [1F40-1F45] [45]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Bepridil and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [45]
Idelalisib DM602WT Moderate Decreased metabolism of Bepridil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [66]
GDC-0199 DMH0QKA Major Decreased clearance of Bepridil due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [57]
Arry-162 DM1P6FR Moderate Decreased clearance of Bepridil due to the transporter inhibition by Arry-162. Melanoma [2C30] [57]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Bepridil and Vemurafenib. Melanoma [2C30] [45]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Bepridil and LGX818. Melanoma [2C30] [45]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Bepridil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [44]
Exjade DMHPRWG Moderate Decreased metabolism of Bepridil caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [67]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Bepridil and Panobinostat. Multiple myeloma [2A83] [45]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Bepridil and Siponimod. Multiple sclerosis [8A40] [57]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Bepridil and Ozanimod. Multiple sclerosis [8A40] [45]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Bepridil and Romidepsin. Mycosis fungoides [2B01] [45]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Bepridil and Nilotinib. Myeloproliferative neoplasm [2A20] [45]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Bepridil and Lofexidine. Opioid use disorder [6C43] [45]
S-297995 DM26IH8 Moderate Decreased clearance of Bepridil due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [44]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Bepridil and Rucaparib. Ovarian cancer [2C73] [45]
MK-4827 DMLYGH4 Moderate Decreased clearance of Bepridil due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [68]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Bepridil and Triclabendazole. Parasitic worm infestation [1F90] [45]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Bepridil and Safinamide. Parkinsonism [8A00] [54]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Bepridil and Rasagiline. Parkinsonism [8A00] [54]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Bepridil and Pimavanserin. Parkinsonism [8A00] [45]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Bepridil and Macimorelin. Pituitary gland disorder [5A60-5A61] [69]
Lefamulin DME6G97 Major Decreased metabolism of Bepridil caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [70]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Bepridil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [71]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Bepridil and Degarelix. Prostate cancer [2C82] [45]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Bepridil and Enzalutamide. Prostate cancer [2C82] [45]
Silodosin DMJSBT6 Moderate Decreased clearance of Bepridil due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [72]
Riociguat DMXBLMP Moderate Decreased clearance of Bepridil due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [57]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Bepridil and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [73]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Bepridil and Iloperidone. Schizophrenia [6A20] [45]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Bepridil and Paliperidone. Schizophrenia [6A20] [45]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Bepridil and Molindone. Schizophrenia [6A20] [48]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Bepridil and Thiothixene. Schizophrenia [6A20] [48]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Bepridil and Amisulpride. Schizophrenia [6A20] [45]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Bepridil and Asenapine. Schizophrenia [6A20] [45]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Bepridil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [44]
Larotrectinib DM26CQR Moderate Decreased clearance of Bepridil due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [57]
Armodafinil DMGB035 Minor Increased metabolism of Bepridil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [74]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Bepridil and LEE011. Solid tumour/cancer [2A00-2F9Z] [45]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Bepridil and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [45]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Bepridil and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [45]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Bepridil and Pitolisant. Somnolence [MG42] [45]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Bepridil and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [45]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Bepridil due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [75]
Apixaban DM89JLN Moderate Decreased clearance of Bepridil due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [44]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Bepridil and Lenvatinib. Thyroid cancer [2D10] [45]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Bepridil and Cabozantinib. Thyroid cancer [2D10] [45]
⏷ Show the Full List of 101 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2337).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
11 Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
31 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
36 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
37 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
38 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
39 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
40 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
41 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
43 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
44 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
45 Canadian Pharmacists Association.
46 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
47 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
48 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
49 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
50 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
51 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
52 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
53 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
54 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
55 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
56 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
57 Cerner Multum, Inc. "Australian Product Information.".
58 Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
59 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
60 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
61 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
62 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
63 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
64 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
65 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
67 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
68 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
69 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
70 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
71 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
72 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
73 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
74 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
75 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".